SCHEMBL8535671

SCHEMBL8535671

c1ccc(P(O[C@@H]2CCCC23CCC[C@H]3OP(c2ccccc2)c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21026748 1.00 TRPA1 (0.30) TRPA1
SCHEMBL12446393 1.00 TRPA1 (0.30) TRPA1
SCHEMBL8536871 1.00 TRPA1 (0.30) TRPA1
SCHEMBL13475447 1.00 TRPA1 (0.30) TRPA1
SCHEMBL12520157 1.00 TRPA1 (0.30) TRPA1
SCHEMBL20169623 1.00 TRPA1 (0.30) TRPA1
SCHEMBL12441134 1.00 TRPA1 (0.30) TRPA1
SCHEMBL15905928 0.92 DPP4 (0.31)
SCHEMBL14015975 0.84
SCHEMBL20347789 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5756799-A HYDROGENATION CATALYSTS FOR OLEFINS USING RHODIUM CATALYST COMPLEXES THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 1998-05-26 US claimed
US-11124528-B2 Process for preparing optically active 2,3-dihydrothiazolo[3,2-A]pyrimidin-4-ium compounds BASF SE (DE) 2021-09-21 US disclosed
US-11034703-B2 Process for preparing chiral 2,3-dihydrothiazolo[3,2-A] pyrimidin-4-ium compounds BASF SE (DE) 2021-06-15 US disclosed
US-20210087207-A1 PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS BASF SE (DE) 2021-03-25 US disclosed
US-20200055872-A1 Process for Preparing Optically Active 2,3-Dihydrothiazolo[3,2-A]pyrimidin-4-ium Compounds BASF SE (DE) 2020-02-20 US disclosed
US-9802887-B2 Process for the preparation of intermediates useful for the manufacture NEP inhibitors NOVARTIS AG (CH) 2017-10-31 US disclosed
EP-2609071-B1 NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE OF NEP INHIBITORS NOVARTIS AG (CH) 2016-09-21 EP disclosed
US-20150274650-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS HOOK DAVID (CH) 2015-10-01 US disclosed
US-9085529-B2 Process for the preparation of intermediates useful for the manufacture NEP inhibitors NOVARTIS AG (CH) 2015-07-21 US disclosed
US-20130158275-A1 NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS NOVARTIS AG (CH) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158275-A1 NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS MME, DNPEP, REN TRPA1 3939/4885
US-20200055872-A1 Process for Preparing Optically Active 2,3-Dihydrothiazolo[3,2-A]pyrimidin-4-ium Compounds UMPS, UGP2, UGT1A4 TRPA1 1508/4885
US-11124528-B2 Process for preparing optically active 2,3-dihydrothiazolo[3,2-A]pyrimidin-4-ium compounds UMPS, UGP2, UGT1A4 TRPA1 1508/4885
US-20150274650-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS MME, DNPEP, REN TRPA1 4188/4885
US-20210087207-A1 PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS UMPS, UGP2, XDH TRPA1 2511/4885
US-11034703-B2 Process for preparing chiral 2,3-dihydrothiazolo[3,2-A] pyrimidin-4-ium compounds UMPS, UGP2, XDH TRPA1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.